Comprehensive value of novel oral anticoagulant drugs after major orthopedic surgery based on multi-criteria decision analysis
- VernacularTitle:基于多准则决策分析评价骨科大手术后新型口服抗凝药物的综合价值
- Author:
Xinru LIU
1
,
2
;
Xindie ZHOU
3
;
Yang YANG
4
;
Jinhong GONG
2
;
Shan XU
2
;
Dan SU
2
;
Jingjing SHANG
2
Author Information
1. School of Pharmacy，Dalian Medical University，Liaoning Dalian 116000，China
2. Dept. of Pharmacy，Changzhou No.2 People’s Hospital Affiliated to Nanjing Medical University，Jiangsu Changzhou 213000，China
3. Dept. of Orthopedics，Changzhou No.2 People’s Hospital Affiliated to Nanjing Medical University，Jiangsu Changzhou 213000，China
4. Dept. of Pharmacy，People’s Hospital of Hainan Tibetan Autonomous Prefecture of Qinghai Province，Qinghai Hainan 813000，China
- Publication Type:Journal Article
- Keywords:
multi-criteria decision analysis;
comprehensive
- From:
China Pharmacy
2025;36(13):1661-1665
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the comprehensive value of novel oral anticoagulant drugs （NOACs） after major orthopedic surgery. METHODS The evaluation evidence was collected through literature research； evidence and value：impact on decision-making （EVIDEM） framework was introduced to integrate the evaluation process； the multi-criteria decision analysis （MCDA） method was used to construct a multi-dimensional evaluation system； the weights assigned to each evaluation criterion were determined by the combination of Delphi method and analytic hierarchy process， and the rivaroxaban， dabigatran and apixaban were comprehensively evaluated. RESULTS The clinical comprehensive evaluation system of NOACs after major orthopedic surgery was successfully established， and the final clinical comprehensive evaluation weights of NOACs （rivaroxaban， dabigatran， apixaban） after major orthopedic surgery were calculated， with scores of 0.399 7 for rivaroxaban， 0.244 4 for apixaban， and 0.355 9 for dabigatran， indicating that rivaroxaban demonstrated the highest overall clinical value. Among them， rivaroxaban had the highest weight score in the evaluation of pharmaceutical characteristics， cost-effectiveness and other attributes in a single dimension. In terms of efficacy and safety evaluation， apixaban had the highest weighting score. CONCLUSIONS Among NOACs， rivaroxaban is more suitable for routine anticoagulation management after major orthopedic surgery， especially in terms of pharmacological properties， cost-effectiveness and other attributes.
